Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

The mission of the Society for Pediatric Research is to cultivate a diverse network of child health researchers through collaboration, community, mentorship, and advocacy. Congratulations to Matthew ...

Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for ...

First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

For the three months ended September 30, 2024, Syndax reported a net loss attributable to common stockholders of $84.1 million, or $0.98 per share, compared to a net loss attributable to common ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million ---- Adult patients with acquired hypothalamic ...

The death of three young Nashville area runners in the past three months have raised questions this TSSAA cross country ...

Hypertension affects 1 in 8 adults aged between 20 and 40 years. The prevalence of hypertension among adults in India is ...

Good morning, ladies and gentlemen and welcome to the Chimerix third quarter, 2024 earnings conference call. I would now like to introduce you to your host for today's call. Will O'Connor from Stern ...

XOMA Royalty recorded total income and revenues of $7.2 million for the third quarter of 2024, which included $6.5 million in estimated income associated with two commercial products in our portfolio.